---
schema_version: "secwatch.filing_event.v1"
accession: "0001804220-22-000029"
form_type: "8-K"
ticker: "REGN"
cik: "0000872589"
company_name: "REGENERON PHARMACEUTICALS, INC."
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T10:50:25.047619+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Regeneron Q3 revenues down 15% to $2.94B; ex-REGEN-COV up 11%; EPS $11.66

## Summary
- GAAP diluted EPS $11.66 (Q3 2021: $14.33); non-GAAP $11.14 ($15.37).
- EYLEA U.S. net sales record $1.63B (+11% YoY); Dupixent global sales $2.33B (+40%).
- Aflibercept 8 mg met primary endpoints in DME and wet AMD pivotal trials; BLA submission planned late 2022.
- FDA granted EYLEA pediatric exclusivity through May 17, 2024; share repurchases $913M in Q3.
- Full-year 2022 GAAP R&D guidance raised to $3.515-$3.600B; SG&A to $2.010-$2.090B.

## SEC filing metadata
- accession: 0001804220-22-000029
- form_type: 8-K
- ticker: REGN
- cik: 0000872589
- company_name: REGENERON PHARMACEUTICALS, INC.
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/872589/000180422022000029/0001804220-22-000029-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/872589/000180422022000029/regn-20221103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001804220-22-000029
- JSON: https://secwatch.observer/filing/0001804220-22-000029.json
- Plain text: https://secwatch.observer/filing/0001804220-22-000029.txt

## Key facts
- Earnings Releases
  REGENERON PHARMACEUTICALS, INC. reported the quarter ended September 30, 2022 results: revenue $2.94 billion, net income $1,316 million, EPS $11.66.
  - Period: the quarter ended September 30, 2022
  - Revenue: $2.94 billion
  - Net income: $1,316 million
  - EPS: $11.66
  - Result: reported results
  source text: EXHIBIT 99.1 Document Exhibit 99.1 Press Release Regeneron Reports Third Quarter 2022 Financial and Operating Results • Third quarter 2022 revenues decreased 15% to $2.94 billion versus third quarter 2021; excluding REGEN-COV ® (a)(b) , revenues increased 11% • Third quarter 2022 EYLEA ® U.S. net sales increased 11% versus third quarter 2021 to a record
  evidence_url: https://www.sec.gov/Archives/edgar/data/872589/000180422022000029/0001804220-22-000029-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.